Evidence map›Paper›PMID 24821775›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.

Behzad Kharabi Masouleh, Huimin Geng, Christian Hurtz, Lai N Chan, Aaron C Logan, Mi Sook Chang, Chuanxin Huang, Srividya Swaminathan, Haibo Sun, Elisabeth Paietta and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Cell surface GRP78 and the UPR pathway as novel promising therapeutic targets in cancer: an insight into the treatment of acute leukemia by using GRP78-CART cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. RNA NExperimental & molecular medicine · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. XBP1 promotes NRASJournal of cellular and molecular medicine · 2023
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Behzad Kharabi MasoulehDepartment of Laboratory Medicine andDepartment of Oncology, Hematology and Stem Cell Transplantation, Rheinisch-Westfaelische Technische Hochschule Aachen University Medical School, 52070 Aachen, Germany;
Huimin GengDepartment of Laboratory Medicine and.
Christian HurtzDepartment of Laboratory Medicine and.
Lai N ChanDepartment of Laboratory Medicine and.
Aaron C LoganDivision of Hematology-Oncology, University of California, San Francisco, CA 94143;
Mi Sook ChangChildren's Hospital Los Angeles, Los Angeles, CA 90027;
Chuanxin HuangDepartments of Medicine andPharmacology, Weill Cornell Medical College, New York, NY 10065;
Srividya SwaminathanDepartment of Laboratory Medicine and.
Haibo SunCedars Sinai Medical Center, Los Angeles, CA 90048; and.
Elisabeth PaiettaDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY 10466.
Ari M MelnickDepartments of Medicine andPharmacology, Weill Cornell Medical College, New York, NY 10065;
Phillip KoefflerCedars Sinai Medical Center, Los Angeles, CA 90048; and.
Markus MüschenDepartment of Laboratory Medicine and markus.muschen@ucsf.edu.
Cedars-Sinai Medical Center · USCornell University · USAlbert Einstein College of Medicine · USChildren's Hospital of Los Angeles · USRWTH Aachen University · DEUniversity of California, San Francisco · US

Funding

Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
ECOG OPERATIONS OFFICE (IBCSG)U10CA021115 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2013
$132.6M
Foreign Accrual - ECOGU10CA037403 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2014
$34.6M
ECOG Specimen BankingU24CA114737 · NCI · FRONTIER SCI &TECHNOLOGY RSCH FDN, INC · PI COMIS, ROBERT L · 2005 to 2014
$9.3M
Targeted activation of autoimmune checkpoints in B cell malignanciesR01CA157644 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2011 to 2026
$5.7M
ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTERU10CA180827 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI LEVINE, ROSS L, MELNICK, ARI M. · 2014 to 2018
$3.0M
PRE-B CELL RECEPTOR SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIAR01CA137060 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2009 to 2016
$2.7M
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemiaR01CA139032 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2009 to 2013
$1.6M
Negative feedback signaling in tyrosine kinase-driven leukemiaR01CA172558 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2013 to 2015
$972k
Targeting BCL6 in tyrosine kinase-driven leukemiaR01CA169458 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2013 to 2015
$972k
Cancer Research UK 18131NCI NIH HHS R01 CA137060NCI NIH HHS R01CA137060NCI NIH HHS R01 CA139032NCI NIH HHS R01CA139032NCI NIH HHS R01 CA157644NCI NIH HHS R01CA157644NCI NIH HHS R01 CA169458NCI NIH HHS R01CA169458NCI NIH HHS R01 CA172558NCI NIH HHS R01CA172558NCI NIH HHS U10 CA021115NCI NIH HHS U10 CA037403NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180827NCI NIH HHS U24 CA114737Wellcome Trust 101880
6 · The paper itself

Abstract

The unfolded protein response (UPR) pathway, a stress-induced signaling cascade emanating from the endoplasmic reticulum (ER), regulates the expression and activity of molecules including BiP (HSPA5), IRE1 (ERN1), Blimp-1 (PRDM1), and X-box binding protein 1 (XBP1). These molecules are required for terminal differentiation of B cells into plasma cells and expressed at high levels in plasma cell-derived multiple myeloma. Although these molecules have no known role at early stages of B-cell development, here we show that their expression transiently peaks at the pre-B-cell receptor checkpoint. Inducible, Cre-mediated deletion of Hspa5, Prdm1, and Xbp1 consistently induces cellular stress and cell death in normal pre-B cells and in pre-B-cell acute lymphoblastic leukemia (ALL) driven by BCR-ABL1- and NRAS(G12D) oncogenes. Mechanistically, expression and activity of the UPR downstream effector XBP1 is regulated positively by STAT5 and negatively by the B-cell-specific transcriptional repressors BACH2 and BCL6. In two clinical trials for children and adults with ALL, high XBP1 mRNA levels at the time of diagnosis predicted poor outcome. A small molecule inhibitor of ERN1-mediated XBP1 activation induced selective cell death of patient-derived pre-B ALL cells in vitro and significantly prolonged survival of transplant recipient mice in vivo. Collectively, these studies reveal that pre-B ALL cells are uniquely vulnerable to ER stress and identify the UPR pathway and its downstream effector XBP1 as novel therapeutic targets to overcome drug resistance in pre-B ALL.

Indexed as

AdultAnimalsBase SequenceBasic-Leucine Zipper Transcription Factorsbeta-GalactosidaseBlotting, WesternB-LymphocytesCell DifferentiationChildChromatin ImmunoprecipitationDNA-Binding ProteinsEndoplasmic Reticulum Chaperone BiPEndoplasmic Reticulum StressEndoribonucleasesFlow CytometryGene DeletionBACH2 protein, humanBasic-Leucine Zipper Transcription FactorsBCL6 protein, humanbeta-GalactosidaseDNA-Binding ProteinsEndoplasmic Reticulum Chaperone BiPEndoribonucleasesERN1 protein, humanHeat-Shock ProteinsHSPA5 protein, humanHspa5 protein, mousePositive Regulatory Domain I-Binding Factor 1PRDM1 protein, humanProtein Serine-Threonine KinasesProto-Oncogene Proteins c-bcl-6Regulatory Factor X Transcription FactorsRepressor ProteinsTranscription FactorsX-Box Binding Protein 1XBP1 protein, humanXbp1 protein, mouse

Identifiers

PMID24821775
PMCPMC4040579
OpenAlexW2112966747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.